We are live on ! Find out more
INGN icon

Inogen

220 hedge funds and large institutions have $2.5B invested in Inogen in 2017 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 80 increasing their positions, 80 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 25

23% more capital invested

Capital invested by funds: $2.03B → $2.5B (+$468M)

6% more funds holding

Funds holding: 208220 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 80

9% less call options, than puts

Call options by funds: $5.42M | Put options by funds: $5.93M

2.51% less ownership

Funds ownership: 103.18%100.68% (-2.5%)

Holders
220
Holders Change
+12
Holders Change %
+5.77%
% of All Funds
4.98%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
38
Increased
80
Reduced
80
Closed
25
Calls
$5.42M
Puts
$5.93M
Net Calls
-$513K
Net Calls Change
-$139K

INGN Hedge Fund Activity: Q4 2017 in Review

220 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Inogen (INGN) for Q4 2017, worth a combined $2.5B — up 23% from $2.03B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new INGN positions and 25 closed out — a net gain of 13 holders — while 80 added to existing stakes and 80 trimmed.

The largest buyer was Millennium Management, adding an estimated $25.2M. The largest seller was PFM Health Sciences, cutting an estimated $16.4M.

  • 220 institutional investors held Inogen (INGN) as of Q4 2017, up from 208 in Q3 2017.
  • Funds reported $2.5B of Inogen stock for Q4 2017, up 23% quarter-over-quarter.
  • 38 funds opened new Inogen positions in Q4 2017 and 25 closed out, a net change of +13 holders.
  • The largest Inogen buyer in Q4 2017 was Millennium Management, an estimated $25.2M added.
  • The largest Inogen seller in Q4 2017 was PFM Health Sciences, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2017.